Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.584 USD | +0.06% | -2.56% | -5.95% |
17/05 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.95% | 18.53M | |
+37.26% | 723B | |
+32.22% | 598B | |
-2.01% | 364B | |
+20.17% | 331B | |
+2.83% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
-5.15% | 208B | |
+8.68% | 169B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Cuts Kala Pharmaceuticals' Price Target $16 From $43, Citing Inveltys, Eysuvis Penetration Estimates; Outperform Rating Kept